Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07VLY
|
||||
| Former ID |
DAP000192
|
||||
| Drug Name |
Doxorubicin
|
||||
| Synonyms |
ADM; ADR; Adriablastin; Adriamycin; Adriblastin; Adriblastina; Doxil; Doxorubicina; Doxorubicine; Doxorubicinum; Myocet; Resmycin; Rubex; ThermoDox; Adriamycin PFS; Adriamycin RDF; Adriamycin semiquinone; Adriblas tina; Aerosolized Doxorubicin; Doxorubicin Hydrochloride; Doxorubicin citrate; RDF Rubex; Triferric doxorubicin; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; FI 106; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Doxorubicina [INN-Spanish]; Doxorubicine [INN-French]; Doxorubicinum [INN-Latin]; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); NDC 38242-874; Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin [USAN:INN:BAN]; Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Sequus Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H29NO11
|
||||
| InChI |
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
|
||||
| InChIKey |
AOJJSUZBOXZQNB-TZSSRYMLSA-N
|
||||
| CAS Number |
CAS 23214-92-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
4809, 596007, 7887074, 7979129, 8172352, 11466466, 11467586, 11486131, 11533222, 11538021, 14910387, 14910388, 17397983, 24769891, 26704333, 26709766, 34673809, 46507641, 47440542, 47515588, 47589229, 47736754, 47811027, 47811028, 48035406, 48185239, 48414671, 48415928, 49698493, 49846798, 49855190, 50063935, 53787595, 53837797, 56310844, 56311108, 56311939, 56312034, 56312063, 56312270, 56312524, 56312768, 56313130, 56313308, 56313325, 56313365, 56313675, 56313990, 56314080, 56314176
|
||||
| ChEBI ID |
ChEBI:28748
|
||||
| SuperDrug ATC ID |
L01DB01
|
||||
| SuperDrug CAS ID |
cas=023214928
|
||||
| Target and Pathway | |||||
| Target(s) | DNA topoisomerase II | Target Info | Modulator | [556264] | |
| References | |||||
| Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| Ref 542075 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7069). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.